Jane Street
TCRR

Jane Street’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Jane Street’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,295
Closed -$41.2K – 10362
2022
Q4 		$41.2K Buy
41,295
+25,553
+162% +$34.4K ﹤0.01% 8428
2022
Q3 		$28K Buy
15,742
+2,541
+19% +$7.37K ﹤0.01% 9114
2022
Q2 		$38K Buy
+13,201
New +$32.6K ﹤0.01% 8996
2022
Q1 		– Sell
-63,142
Closed -$294K – 11330
2021
Q4 		$294K Buy
63,142
+51,949
+464% +$325K ﹤0.01% 8199
2021
Q3 		$95K Buy
+11,193
New +$158K ﹤0.01% 9330
2021
Q2 		– Sell
-46,940
Closed -$948K – 10656
2021
Q1 		$1.04M Buy
46,940
+22,562
+93% +$615K ﹤0.01% 5383
2020
Q4 		$754K Buy
+24,378
New +$616K ﹤0.01% 5116

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jane Street's TCRR Position: Q1 2023 in Review

Jane Street sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 41,295 shares — an estimated $41.2K sold.

Jane Street first reported a position in TCRR in Q4 2020 and held it in 7 quarters. The position peaked at $1.04M in Q1 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • Jane Street reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jane Street sold 41,295 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $41.2K.
  • Jane Street first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Jane Street's TCR2 Therapeutics Inc. Common Stock position peaked at $1.04M in Q1 2021.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.